Summit Therapeutics Plc Stock Today

SMMT Stock  USD 4.14  0.39  10.40%   

Performance

10 of 100

 
Low
 
High
OK

Odds Of Distress

Less than 9

 
100  
 
Zero
Low
Summit Therapeutics is selling for under 4.14 as of the 29th of March 2024; that is 10.40 percent increase since the beginning of the trading day. The stock's last reported lowest price was 4.1. Summit Therapeutics has less than a 9 % chance of experiencing financial distress in the next few years and had a ok performance during the last 90 days. Equity ratings for Summit Therapeutics PLC are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of April 2022 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
5th of March 2015
Category
Healthcare
Classification
Health Care
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. The company was founded in 2003 and is based in Cambridge, Massachusetts. Summit Therapeu operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 701.7 M outstanding shares of which 16.96 M shares are at this time shorted by private and institutional investors with about 6.85 trading days to cover. More on Summit Therapeutics PLC

Moving together with Summit Stock

  0.69CLVRW Clever Leaves HoldingsPairCorr
  0.61EQ Equillium Financial Report 9th of May 2024 PairCorr

Moving against Summit Stock

  0.84VALN Valneva SE ADR Financial Report 2nd of May 2024 PairCorr
  0.76MEIP MEI Pharma Financial Report 9th of May 2024 PairCorr
  0.61MGTX MeiraGTx Holdings PLC Financial Report 9th of May 2024 PairCorr
  0.53ME 23Andme HoldingPairCorr
  0.52MCRB Seres Therapeutics Financial Report 14th of May 2024 PairCorr
  0.51KA Kineta Inc Financial Report 9th of May 2024 PairCorr
  0.5VAXX Vaxxinity Financial Report 14th of May 2024 PairCorr

Summit Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Summit Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Summit Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO, Executive DirectorGlyn Edwards
Thematic Ideas
(View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Biotech, Israel Wall Street, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Summit Therapeutics report their recommendations after researching Summit Therapeutics' financial statements, talking to executives and customers, or listening in on Summit Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Summit Therapeutics PLC. The Summit consensus assessment is calculated by taking the average forecast from all of the analysts covering Summit Therapeutics.
Financial Strength
Based on the key indicators related to Summit Therapeutics' liquidity, profitability, solvency, and operating efficiency, Summit Therapeutics PLC is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April. Financial strength of Summit Therapeutics PLC is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover9.0E-40.001
Notably Down
Slightly volatile
Total Current Liabilities11 M20.4 M
Way Down
Slightly volatile
Non Current Liabilities Total110.1 M104.9 M
Sufficiently Up
Slightly volatile
Total Assets213.1 M202.9 M
Sufficiently Up
Slightly volatile
Total Current Assets199.2 M189.7 M
Sufficiently Up
Slightly volatile
Summit Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Summit Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Summit Therapeutics' financial leverage. It provides some insight into what part of Summit Therapeutics' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Summit Therapeutics' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Summit Therapeutics deploys its capital and how much of that capital is borrowed.
Liquidity
Summit Therapeutics cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 106.1 M in liabilities with Debt to Equity (D/E) ratio of 0.03, which may suggest the company is not taking enough advantage from borrowing. Summit Therapeutics PLC has a current ratio of 8.06, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Summit Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Summit Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Summit Therapeutics PLC sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Summit to invest in growth at high rates of return. When we think about Summit Therapeutics' use of debt, we should always consider it together with cash and equity.

Total Cash From Operating Activities

(72.92 Million)
Summit Therapeutics PLC (SMMT) is traded on NASDAQ Exchange in USA. It is located in 601 Brickell Key Drive, Miami, FL, United States, 33131 and employs 105 people. Summit Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.91 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Summit Therapeutics's market, we take the total number of its shares issued and multiply it by Summit Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Summit Therapeutics PLC conducts business under Biotechnology sector and is part of Health Care industry. The entity has 701.7 M outstanding shares of which 16.96 M shares are at this time shorted by private and institutional investors with about 6.85 trading days to cover. Summit Therapeutics PLC currently holds about 121.97 M in cash with (76.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.61.
Check Summit Therapeutics Probability Of Bankruptcy
Ownership Allocation
Summit Therapeutics PLC shows a total of 701.7 Million outstanding shares. Summit Therapeutics PLC has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 88.13 % of Summit Therapeutics outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Summit Ownership Details

Summit Stock Price Odds Analysis

Attributed to a normal probability distribution, the odds of Summit Therapeutics jumping above the current price in 90 days from now is about 35.19%. The Summit Therapeutics PLC probability density function shows the probability of Summit Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.2456. This usually implies as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Summit Therapeutics will likely underperform. Additionally, summit Therapeutics PLC has an alpha of 0.9395, implying that it can generate a 0.94 percent excess return over NYSE Composite after adjusting for the inherited market risk (beta).
  Odds Below 4.14HorizonTargetOdds Above 4.14
64.72%90 days
 4.14 
35.19%
Based on a normal probability distribution, the odds of Summit Therapeutics to move above the current price in 90 days from now is about 35.19 (This Summit Therapeutics PLC probability density function shows the probability of Summit Stock to fall within a particular range of prices over 90 days) .

Summit Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Summit Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Summit Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Summit Therapeutics' value.
InstituionRecorded OnShares
Bank Of New York Mellon Corp2023-12-31
342.5 K
Barclays Plc2023-12-31
318.6 K
Jpmorgan Chase & Co2023-12-31
296.2 K
Swiss National Bank2023-12-31
275 K
Susquehanna International Group, Llp2023-12-31
230.3 K
First Trust Advisors L.p.2023-12-31
170.2 K
Ubs Group Ag2023-12-31
151.3 K
Advisor Group Holdings, Inc.2023-12-31
144 K
California State Teachers Retirement Sys2023-12-31
143.2 K
Blackrock Inc2023-12-31
9.8 M
Vanguard Group Inc2023-12-31
M
View Summit Therapeutics Diagnostics

Summit Therapeutics Historical Income Statement

Summit Therapeutics PLC Income Statement is one of the three primary financial statements used for reporting Summit's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Summit Therapeutics PLC revenue and expense. Summit Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Summit Therapeutics' Interest Expense is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 31.8 M in 2024, despite the fact that Gross Profit is likely to grow to (1.9 M). View More Fundamentals

Summit Stock Against Markets

Picking the right benchmark for Summit Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Summit Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Summit Therapeutics is critical whether you are bullish or bearish towards Summit Therapeutics PLC at a given time. Please also check how Summit Therapeutics' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Summit Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Theme Ratings Now

   

Theme Ratings

Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
All  Next Launch Module

Summit Therapeutics Corporate Directors

Summit Therapeutics corporate directors refer to members of a Summit Therapeutics board of directors. The board of directors generally takes responsibility for the Summit Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Summit Therapeutics' board members must vote for the resolution. The Summit Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Abed NegoCorporate Secretary, DirectorProfile
Barry PriceNon-Executive DirectorProfile
David WurzerNon-Executive DirectorProfile
Achmad HawadiUnaffiliated DirectorProfile

How to buy Summit Stock?

Before investing in Summit Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Summit Therapeutics. To buy Summit Therapeutics stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Summit Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Summit Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Summit Therapeutics PLC stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Summit Therapeutics PLC stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Summit Therapeutics PLC, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Summit Stock please use our How to Invest in Summit Therapeutics guide.

Already Invested in Summit Therapeutics PLC?

The danger of trading Summit Therapeutics PLC is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Summit Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Summit Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Summit Therapeutics PLC is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Summit Therapeutics PLC is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Summit Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Summit Therapeutics Plc Stock. Highlighted below are key reports to facilitate an investment decision about Summit Therapeutics Plc Stock:
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Summit Therapeutics PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for Summit Stock analysis

When running Summit Therapeutics' price analysis, check to measure Summit Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Summit Therapeutics is operating at the current time. Most of Summit Therapeutics' value examination focuses on studying past and present price action to predict the probability of Summit Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Summit Therapeutics' price. Additionally, you may evaluate how the addition of Summit Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Stocks Directory
Find actively traded stocks across global markets
Is Summit Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Summit Therapeutics. If investors know Summit will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Summit Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.99)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.13)
Return On Equity
(6.02)
The market value of Summit Therapeutics PLC is measured differently than its book value, which is the value of Summit that is recorded on the company's balance sheet. Investors also form their own opinion of Summit Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Summit Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Summit Therapeutics' market value can be influenced by many factors that don't directly affect Summit Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Summit Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Summit Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Summit Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.